How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Monkeypox Therapeutics Market
- By Therapeutic Type: Antiviral Drugs, Vaccines, Monoclonal Antibodies, Supportive Care Agents
- By Drug Class: Nucleoside Analogues, Protease Inhibitors, Immunomodulators, Small Molecule Inhibitors
- By Route of Administration: Oral, Intravenous, Subcutaneous, Topical
- By Patient Type: Adult Patients, Pediatric Patients, Immunocompromised Patients
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Antiviral Drugs leads By Therapeutic Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Monkeypox Therapeutics Market report
A complete, evidence-based study - 12 chapters and 116 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Type 4
Drug Class 4
Route of Administration 4
Patient Type 3
Distribution Channel 3
Companies profiled
SIGA Technologies
Bavarian Nordic
Emergent BioSolutions
Janssen Pharmaceuticals (Johnson & Johnson)
Moderna
Pfizer
Gilead Sciences
Sanofi
GlaxoSmithKline
Novavax
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →SIGA Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bavarian Nordic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Emergent BioSolutions
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Janssen Pharmaceuticals (Johnson & Johnson)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Moderna
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Pfizer
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Gilead Sciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sanofi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →GlaxoSmithKline
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Novavax
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,983M by 2033 · 6.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Antiviral Drugs66.7
- Vaccines13.4
- Monoclonal Antibodies8.2
- Supportive Care Agents11.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$614.1M → $945.0M · 5.5%
Europe$428.0M → $693.0M · 6.2%
Asia Pacific$390.8M → $567.6M · 4.8%
Latin America$241.9M → $420.9M · 7.2%
Middle East and Africa$186.1M → $279.5M · 5.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.032026
6.042027
6.042028
6.052029
6.072030
6.092031
6.092032
6.122033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- SIGA Technologies20.2
- Bavarian Nordic13.0
- Emergent BioSolutions8.3
- Janssen Pharmaceuticals (Johnson & Johnson)10.9
- Moderna6.0
- Pfizer13.5
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Type15.0%
Drug Class18.5%
Route of Administration19.9%
Patient Type22.4%
Distribution Channel24.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.5
- Europe23.8
- Asia Pacific19.5
- Latin America14.5
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| SIGA Technologies | 92 | 77 | 79 | 74 | 82 | 97 | 84 |
| Bavarian Nordic | 71 | 79 | 86 | 89 | 86 | 87 | 83 |
| Emergent BioSolutions | 86 | 64 | 76 | 74 | 77 | 63 | 73 |
| Janssen Pharmaceuticals (Johnson & Johnson) | 64 | 79 | 74 | 72 | 58 | 76 | 71 |
| Moderna | 57 | 63 | 66 | 53 | 52 | 76 | 61 |
| Pfizer | 68 | 54 | 61 | 55 | 58 | 69 | 61 |
| Gilead Sciences | 61 | 63 | 46 | 52 | 54 | 46 | 54 |
| Sanofi | 41 | 41 | 52 | 60 | 59 | 35 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- SIGA Technologies
- Bavarian Nordic
- Emergent BioSolutions
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| SIGA Technologies | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Bavarian Nordic | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Emergent BioSolutions | ✓ | − | ✓ | ◐ | ◐ | − |
| Janssen Pharmaceuticals (Johnson & Johnson) | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Moderna | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Pfizer | ◐ | ◐ | ◐ | − | − | − |
| Gilead Sciences | − | ◐ | − | ◐ | ◐ | − |
| Sanofi | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1SIGA Technologies84
2Bavarian Nordic83
3Emergent BioSolutions73
4Janssen Pharmaceuticals (Johnson & Johnson)71
5Moderna61
6Pfizer61
7Gilead Sciences54
8Sanofi48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
SIGA TechnologiesBavarian Nordic
Challenger2
Strong scale, closing on the leaders.
Emergent BioSolutionsJanssen Pharmaceuticals (Johnson & Johnson)
Contender2
Focused players with pockets of strength.
ModernaPfizer
Niche2
Specialists in a single segment or region.
Gilead SciencesSanofi
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Type in North America, then scale across Monkeypox Therapeutics Market — a $536M beachhead inside a $7.74B market.
Beachhead (SOM)$536Mobtainable near-term
Serviceable (SAM)$2.83Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Antiviral Drugs
Best fit — highest urgency & budget in Therapeutic Type.
Economic buyer77 fit
Vaccines
Strong fit — clear ROI and a fast path to value.
End user65 fit
Monoclonal Antibodies
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Monkeypox Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified24%
Evaluation14%
Closed-won6%
$20.6KCAC
$85KLTV
4.1:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Monkeypox Therapeutics Market is a durable-growth opportunity — $5.78B by 2033, compounding at 8.5%.
TAM · 2025$3.01Btoday
TAM · 2033$5.78Bforecast
CAGR8.5%2027–2033
Cumulative$38.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.78BTotal addressable market
SAM$1.97BServiceable available market
SOM$371MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.5% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.78BLarge & growingTAM by 2033 at 8.5% CAGR
$1.97BServiceable nowreachable with today’s model
$371MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.51BBear5.5% CAGR
$5.78BBase8.5% CAGR
$7.40BBull11.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Monkeypox Therapeutics Market — a $2.27B market by 2033. Plan: grow share from 6.7% to 14.4%.
Market size · 2033$2.27Btotal addressable
Market CAGR10.0%2027–2033
Target share14.4%from 6.7% today
Revenue ambition$327Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.7% | 14.4% | Ahead |
| Revenue | $158M | $327M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 34.8% | 46.0% | On track |
| Customer retention | 87.5% | 93.3% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $37M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Monkeypox Therapeutics Market conversation — a $6.99B market you can size, segment and defend in minutes.
Market size · 2033$6.99Btotal opportunity
Growth3.7%CAGR to 2033
Addressable buyers1,579+accounts in scope
Typical ROI7.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Type
Goal Grow share in Therapeutic Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.2×return on cost, year one
< 2 mopayback period
$51K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
SIGA TechnologiesBavarian NordicEmergent BioSolutionsJanssen Pharmaceuticals (Johnson & Johnson)ModernaPfizerGilead SciencesSanofi+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Monkeypox Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Monkeypox Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Monkeypox Test Kit Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportMonkeypox Testing Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportMonkeypox Diagnostic Kit Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportMonkeypox Assay Kit Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportMonkey IL-6 ELISA Kit Market
Market size, share, segmentation and regional forecast.
$903M market · 2025 base year
View reportMonitoring Wristband Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportMonitoring System during Anesthesia Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportMonitoring ECG Electrodes Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportMomordica Charantia Peptide Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportMometasone Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportMometasone Furoate Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportMometasone Furoate Cream Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.